Literature DB >> 9886401

A NF-kappa B/c-myc-dependent survival pathway is targeted by corticosteroids in immature thymocytes.

W Wang1, J Wykrzykowska, T Johnson, R Sen, J Sen.   

Abstract

Glucocorticoid hormones modulate T cell maturation in vivo. While low levels of hormones are required for appropriate T cell development, high levels of glucocorticoid hormones target immature developing thymocytes for cell death during systemic stress. In this report, we propose a molecular mechanism for the induction of apoptosis in CD4+CD8+ double-positive thymocytes by dexamethasone in vivo. Dexamethasone injection induced the expression of IkappaBalpha and IkappaBbeta in thymocytes and down-regulated NF-kappaB DNA binding activated by intrathymic signals. Down-regulation of NF-kappaB DNA binding preceded cell death, suggesting that NF-kappaB may be important for the survival of immature thymocytes. In addition, ex vivo treatment of thymocyte single-cell suspension with dexamethasone accelerated p65/RelA down-regulation and cell death. Conversely, NF-kappaB induction diminished dexamethasone-induced death. Expression of the c-myc proto-oncogene, a NF-kappaB target, was also reduced in thymocytes of dexamethasone-treated animals, and ectopic transgenic expression of c-myc in mice provided partial rescue of double-positive thymocytes from dexamethasone mediated cell death. These observations suggest that viability of CD4+CD8+ thymocytes may be maintained by an NF-kappaB/c-myc-dependent pathway in vivo.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9886401

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Protective effects of anti-C5a in sepsis-induced thymocyte apoptosis.

Authors:  R F Guo; M Huber-Lang; X Wang; V Sarma; V A Padgaonkar; R A Craig; N C Riedemann; S D McClintock; T Hlaing; M M Shi; P A Ward
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

2.  Essential role of TAK1 in thymocyte development and activation.

Authors:  Hong-Hsing Liu; Min Xie; Michael D Schneider; Zhijian J Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-20       Impact factor: 11.205

3.  Glucocorticoids potently block tumour necrosis factor-alpha- and lipopolysaccharide-induced apoptotic cell death in bovine glomerular endothelial cells upstream of caspase 3 activation.

Authors:  U K Messmer; G Winkel; V A Briner; J Pfeilschifter
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

4.  Glucocorticoid receptor alpha isoform-selective regulation of antiapoptotic genes in osteosarcoma cells: a new mechanism for glucocorticoid resistance.

Authors:  Katherine L Gross; Robert H Oakley; Alyson B Scoltock; Christine M Jewell; John A Cidlowski
Journal:  Mol Endocrinol       Date:  2011-04-28

5.  The microRNA miR-181 is a critical cellular metabolic rheostat essential for NKT cell ontogenesis and lymphocyte development and homeostasis.

Authors:  Jorge Henao-Mejia; Adam Williams; Loyal A Goff; Matthew Staron; Paula Licona-Limón; Susan M Kaech; Maki Nakayama; John L Rinn; Richard A Flavell
Journal:  Immunity       Date:  2013-04-25       Impact factor: 31.745

6.  Role of caspases in dexamethasone-induced apoptosis and activation of c-Jun NH2-terminal kinase and p38 mitogen-activated protein kinase in human eosinophils.

Authors:  J P Zhang; C K Wong; C W Lam
Journal:  Clin Exp Immunol       Date:  2000-10       Impact factor: 4.330

7.  Glucocorticoids induce G1 cell cycle arrest in human neoplastic thymic epithelial cells.

Authors:  Yasunobu Funakoshi; Hiroyuki Shiono; Masayoshi Inoue; Yoshihisa Kadota; Mitsunori Ohta; Hikaru Matsuda; Meinoshin Okumura; Tadaaki Eimoto
Journal:  J Cancer Res Clin Oncol       Date:  2005-02-10       Impact factor: 4.553

Review 8.  Development of novel treatment strategies for inflammatory diseases-similarities and divergence between glucocorticoids and GILZ.

Authors:  Qiang Cheng; Eric Morand; Yuan Hang Yang
Journal:  Front Pharmacol       Date:  2014-07-17       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.